Article
Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers.
Nature communications - 30 May 2025
Lehrich Brandon M, Delgado Evan R, Yasaka Tyler M, Liu Silvia, Cao Catherine, Liu Yuqing, Taheri Mohammad N, Guan Xiangnan, Koeppen Hartmut, Singh Sucha, Meadows Vik, Liu Jia-Jun, Singh-Varma Anya, Krutsenko Yekaterina, Poddar Minakshi, Hitchens T Kevin, Foley Lesley M, Liang Binyong, Rialdi Alex, Rai Ravi P, Patel Panari, Riley Madeline, Bell Aaron, Raeman Reben, Dadali Tulin, Luke Jason J, Guccione Ernesto, Ebrahimkhani Mo R, Lujambio Amaia, Chen Xin, Maier Martin, Wang Yulei, Broom Wendy, Tao Junyan, Monga Satdarshan P
Abstract excerpt
First-line immune checkpoint inhibitor (ICI) combinations show responses in subsets of hepatocellular carcinoma (HCC) patients. Nearly half of HCCs are Wnt-active with mutations in CTNNB1 (encoding for β-catenin), AXIN1/2, or APC, and demonstrate heterogeneous and limited benefit to ICI due to an immune excluded tumor microenvironment. We show significant tumor responses in multiple β-catenin-mutated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.